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Objectives: Paragangliomas of the head and neck and cranial base are typically benign, slow-growing tumors arising
within the jugular foramen, middle ear, carotid bifurcation, or vagus nerve proper. The objective of this study was to provide
a comprehensive characterization of our institutional experience with clinical management of these tumors and posit an algo-
rithm for diagnostic evaluation and treatment.
Methods: This was a retrospective cohort study of patients undergoing treatment for paragangliomas of the head and
neck and cranial base at our institution from 2000–2017. Data on tumor location, catecholamine levels, and specific imaging
modalities employed in diagnostic work-up, pre-treatment cranial nerve palsy, treatment modality, utilization of preoperative
angiographic embolization, complications of treatment, tumor control and recurrence, and hereditary status (ie, succinate
dehydrogenase mutations) were collected and summarized.
Results: The mean (SD) age of our cohort was 51.8 (616.1) years with 123 (63.4%) female patients and 71 (36.6%)
male patients. Catecholamine-secreting lesions were found in nine (4.6%) patients. Fifty-one patients underwent genetic test-
ing, with mutations identified in 43 (20 SDHD, 13 SDHB, 7 SDHD, 1 SDHA, SDHAF2, and NF1). Observation with serial imaging,
surgical extirpation, radiation, and stereotactic radiosurgery were variably employed as treatment approaches across anatomic
subsites.
Conclusion: An algorithmic approach to clinical management of these tumors, derived from our longitudinal institu-
tional experience and current empiric evidence, may assist otolaryngologists, radiation oncologists, and geneticists in the care
of these complex neoplasms.
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INTRODUCTION
Paragangliomas are rare, hypervascular neoplasms
arising from neural crest-derived cell clusters in the head
and neck/cranial base, mediastinum, abdomen, and pel-
vis.1 With an overall incidence of 1 in 30,000–100,000,
head and neck paragangliomas (HNPGLs) arise, in order
of decreasing frequency, from the carotid body (carotid
body paragangliomas, CBP), jugular bulb (JP), vagus
nerve (cranial nerve [CN] X; VP), the tympanic branch of
the glossopharyngeal (CN IX) or auricular branch of CN X
(TP), and the cervical sympathetic chain (SCP).2
As many as 40% of HNPGLs are now known to
arise in patients with a hereditary predisposition. Most
commonly implicated are germline mutations in one of
the four subunits (A-D) of the succinate dehydrogenase
complex of the mitochondrial electron transport chain
and its flavination co-factor (SDHA-D, SDHAF2, collec-
tively referred to as SDHx).3,4 Screening for pathologic
SDHx mutations in all patients with incident HNPGL
diagnosis is now the standard of care.5 Though HNPGLs
are infrequent secretors (< 3% of tumors) of catechol-
amines, laboratory evaluation of plasma and/or urine
catecholamine metabolites should be included in the
diagnostic workup to identify the rare secreting HNPGL
and, far more importantly, a concomitant pheochromocy-
toma.6 Contrast-enhanced cross-sectional imaging by
computer axial tomography (CT) or magnetic resonance
imaging (MRI) of the head and neck/cranial base are
essential tools to delineate the extent of disease, includ-
ing great vessel involvement, expected CN anatomy,
temporal bone or intracranial extension of HNPGL, and
to exclude the presence of multifocal tumors.7,8
The principal treatment approaches for HNPGL
include surgery, fractionated radiation, and stereotactic
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radiosurgery, although observation with serial imaging
may also be considered.9 Recommendations for HNPGL
treatment depend on a number of factors. First,
HNPGLs exhibit an indolent growth pattern, with an
average tumor-doubling time of 4.2–5.5 years,10,11 and
are seldom malignant.12 Second, fractionated radiation
therapy (eg, 45–50 Gy), stereotactic radiosurgery (SRS),
and surgery offer comparable 10-year control rates,
HNPGL-specific survival, and distant-metastasis free
survival, all in excess of 97%.13,14 As operative morbidity
to CNs VII–XII is often unavoidable, radiation or SRS
may offer improved functional outcomes with regard to
speech, swallowing, and facial nerve and shoulder
function. As such, a steadily-increasing proportion of
patients with HNPGL are being treated with non-
curative or debulking surgery with preservation of
CNs followed by adjuvant radiation, or exclusively by
non-surgical therapies.15,16 Finally, patient-related fac-
tors, including age and goals of care, medical comor-
bidities, and genetic status also serve as critical
factors to consider before embarking on any specific
treatment path.
Ultimately, clinical management of these tumors
remains challenging owing to heterogeneity in clinical
presentation, existence of multiple treatment alterna-
tives, and potential to cause serious detriment to criti-
cal functions of the head and neck.17 Herein, we
provide a report of our institutional experience with
194 patients with HNPGLs from 2000–2017, with an
emphasis on our approach to clinical evaluation, treat-
ment, and genetic investigation of CBP, JP, VP, TP,
SCP, and multi-focal HNPGL patient cohorts. Finally,
we posit an evidence-based algorithm for multi-
disciplinary clinical evaluation and management of
these diverse neoplasms.
MATERIALS AND METHODS
Following approval by the University of Michigan Institu-
tional Review Board (HUM00120115), a retrospective medical
record review was conducted of 194 patients with 233 paragan-
gliomas (228 HNPGL, five concomitant mediastinal/abdominal
paragangliomas or pheochromocytoma) who underwent treat-
ment at our institution from 2000–2017. DataDirect18 and
EMERSE19 search functions were utilized to identify patients
from the electronic health record for inclusion in our study.
Data on patient demographics, tumor characteristics, initial CN
deficits and signs and symptoms at presentation, diagnostic
evaluation, treatment, follow-up, and results of genetic evalua-
tions were collected.
HNPGL size was determined by anatomic pathology or
head and neck MRI, in cases of non-surgical treatment
approaches. Tumors were considered functional (ie, catechol-
amine-secreting) when patients had plasma or urine meta-
nephrine levels elevated 1.5 times our laboratory’s reference
range. Duration of clinical follow-up was defined as the time
interval from the date of treatment (ie, surgery or final dose of
radiation) or first patient encounter (for patients observed) to
the last clinical evaluation or patient death.
Descriptive statistics and student’s t-test (two-tailed,
a5 0.05) were performed using SPSS (Version 22.0, Chicago,
Illinois, U.S.A.).
RESULTS
Patient Demographics & Paraganglioma
Localization
The mean (SD) age of our cohort was 51.8 (616.1)
years with a range of 13.7 to 85.2 years. Of 194 patients,
123 (63.4%) were female and 71 (36.6%) were male. The
distribution of HNPGL sub-sites is depicted in Figure 1,
panel A. A patient index and detailed localization of
multi-focal and/or metastatic paragangliomas is pre-
sented in Figure 1, panel B.
Genetic Testing for Hereditary Paraganglioma-
Pheochromocytoma Syndromes
Genetic testing for SDHx variants become widely
adopted only after 2008. In our entire cohort of HNPGL
patients, 51 (26.3%) underwent genetic counseling and
testing, 44 of which were diagnosed with HNPGL in
2008 or later. Of the 51 patients undergoing genetic test-
ing, 43 (84.3%) were confirmed to carry a pathogenic
mutation in a known susceptibility gene. Mutations in
SDHD were most common (20/43, 46.5%), followed by
SDHB (13/43, 30.2%), and SDHC (7/43, 16.3%). Patho-
genic mutations in SDHA, SDHAF2, and NF1 were
identified in the final three patients with unilateral
CBP, unilateral CBP, and SCP with concomitant bilat-
eral pheochromocytoma, respectively. The highest fre-
quency of SDHx mutations was seen in patients with
SCP, multi-focal or metastatic HNPGL, and bilateral
CBP (100.0% of patients tested within each cohort).
Carotid Body Paraganglioma (Unilateral)
Depicted in Figure 2 is a flow diagram detailing
patient demographics, presenting signs and symptoms,
diagnostic evaluation, tumor characteristics, treatment,
and follow-up for our cohort of patients with solitary
unilateral CBP. The most common presentation of uni-
lateral CBP was painless, enlarging neck mass (30
patients, 48.4%). Pre-treatment CN palsy was rare, with
only three patients (4.8%) presenting with cranial nerve
X or XII weakness on initial physical exam. Similarly,
functional CBP were rare, with notable metanephrine
elevations in only four of 24 patients in whom meta-
nephrines were assessed pre-treatment. During the
study period, a single patient was diagnosed with a
malignant, unilateral CBP based on aggressive soft-
tissue extension into the brachial plexus and cervical
nerve roots; this patient was treated with sub-total
resection and adjuvant radiation.
Among 49 patients with CBP treated initially with
surgery, 25 patients first underwent preoperative angio-
graphic embolization. There was no difference in CBP
size between patients undergoing preoperative emboliza-
tion versus those that did not (3.86 1.2 cm vs. 3.46
1.6 cm, p5 0.337). Preoperative tumor embolization was
complicated by new CN weakness in two patients (CN X,
XII, respectively) and a right, fronto-parietal ischemic
stroke in one patient, precluding definitive treatment of
CBP. Among the 12 patients with CBP initially undergo-
ing a “wait and scan” approach, 2 (16.7%) eventually
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underwent extirpation due to CBP growth, with a mean
time interval to treatment of 5.8 years.
Carotid Body Paraganglioma (Bilateral)
The mean (SD) age of the bilateral CBP patient
cohort (14 patients) was 49.0 (611.9) years, with a gen-
der distribution of 8 (57.1%) females and 6 (42.9%)
males. No patients with bilateral CBP exhibited CN dys-
function at presentation, and all tumors were non-
secreting, benign paragangliomas. A staged surgical
excision of bilateral CBP was performed in 8/14 patients
with a mean (range) time interval of 11 (0.1–72) months
between operations. Seven of these staged excisions
began with the larger of the bilateral CBP. Staged surgi-
cal excisions of bilateral CBP resulted in development of
new CN palsies in two patients (unilateral CN X weak-
ness, unilateral CN XII weakness and bilateral Horner’s
syndrome, respectively). Additionally, 5/8 patients
(62.5%) were treated for new-onset hypertension due to
baroreceptor dysfunction in the postoperative period.
Surgical excision of the larger CBP and observation
with serial imaging of the smaller, contralateral tumor
was the treatment strategy for four of 14 bilateral CBP
patients. The mean (range) duration of observation for
the smaller of bilateral CBP was 73 (6–140) months with
Fig. 1. Localization of paraganglioma (s) of the head and neck in 194 patients at our institution from 2000–2017. Panel A: Frequency histo-
gram depicting total patients and patients with confirmed mutations in SDHx gene by paraganglioma location (Other paraganglioma:
includes parotid gland/CN VII paraganglioma, infratemporal-pterygopalatine paraganglioma, and gangliocytic paraganglioma of skull base.
Panel B: Index and localization of 24 patients with multi-focal or metastatic paragangliomas. bilat5bilateral; CBP5carotid body paragan-
gliomal; CNM5 cervical nodal metastases; FLM5 frontal lobe metastases; GPP5glossopharyngeal paraganglioma; JP5 jugular paragan-
glioma; L5 left-sided; MP5mediastinal paraganglioma; PAP5para-aortic paraganglioma; Pheo5pheochromocytoma; PM5pulmonary
metastases; R5 right-sided; SCP5 sympathetic chain paraganglioma; SGP5 supraglottic paraganglioma; SLNP5 superior laryngeal nerve
paraganglioma; TP5 tympanic paraganglioma; VM5 vertebral body metastases; VP5 vagal paraganglioma. † Paragangliomas developed
sequentially. ‡ Metastatic disease
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Fig. 2. Diagnostic evaluation & treatment of patients (n5 62) with solitary, unilateral carotid body tumors (CBP). † CN IX, X, XII. ‡ External
carotid artery, lingual artery, superior thyroid artery, thyrocervical trunk, superior thyroid artery, and internal jugular vein. § CN VII, marginal
mandibular branch: 4 patients, CN IX: 3 patients, CN X: 10 patients, CN XI: 2 patients, CN XII: 8 patients, cervical sympathetic trunk: 3
patients
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no patients requiring additional treatment for CBP
growth or new symptoms during the observation period.
The final two patients were diagnosed with small,
asymptomatic bilateral CBP within the last three years
and have been observed during this time frame.
Jugular Paraganglioma
The flow diagram for the diagnostic evaluation and
treatment of 41 patients with solitary JP is depicted in
Figure 3. The highest frequency of pre-treatment CN
deficits was seen in the JP cohort, with 28/41 (68.3%)
patients presenting with dysfunction of one or more CNs
(IX, X, XI, XII). Primary treatment modalities for JP
varied; 16 (39.0%) underwent surgical excision of JP, 11
(26.8%) received conventional fractionated radiation,
four (9.8%) underwent SRS, and 10 (24.4%) were fol-
lowed with serial imaging. Like the CBP cohort, tumor
size was similar between embolized and non-embolized
JP (3.562.0 cm vs. 3.06 1.7 cm, p5 0.675). Emboliza-
tion was complicated in two patients by new CN IX–X
deficits and bilateral punctate thalamic strokes, respec-
tively. In almost all cases, our surgeons opted for a sub-
total resection with CN preservation (14/16 operations),
with adjuvant radiation to the jugular foramen in 8/14
patients.
Vagal Paraganglioma
Figure 4 depicts the flow diagram for the diagnostic
evaluation and treatment of 21 patients with solitary
VP. Evidence of CN X palsy and unilateral vocal cord
dysfunction was observed in seven (33.3%) patients at
presentation. VP were the largest of any HNPGL in our
cohort, with a mean (SD) tumor size of 5.3 (61.9) cm.
One patient was diagnosed with malignant VP, again
due to aggressive cervical soft-tissue discovered on post-
surgical pathology. Surgical excision with preoperative
embolization of VP was the most common treatment
path (11/2, 52.4%). Surgery resulted in complete unilat-
eral CN X palsy in all patients, with additional postoper-
ative deficits including CN IX, XII, and the cervical
sympathetic chain in two patients.
Tympanic Paraganglioma
The mean (SD) age of the TP cohort (n5 22) was
60.3 (613.8) years, with a gender distribution of 19
(86.4%) females and 3 (13.6%) males. Unilateral pulsa-
tile tinnitus (13/22, 59.1%) and conductive hearing loss
(7/22, 31.8%) were the most common presenting symp-
toms of TP. All TP were benign tumors, with a mean
(SD) tumor size of 0.7 (60.6) cm, the smallest HNPGL
in our entire cohort. Of the 19 patients with TP undergo-
ing surgical excision, none experienced postoperative
complications or developed recurrence during the follow-
up period (mean 12.1 months). The remaining three
patients with TP were observed, with none requiring
definitive TP treatment during a mean observation
period of 24 months.
Sympathetic Chain Paraganglioma
The seven patients with solitary SCP were compar-
atively younger than other HNPGL groups, with a mean
(SD) patient age of 32.7 (610.6) years. Of six patients
with symptomatic SCP at presentation, four (57.1%) had
evidence of unilateral Horner’s syndrome and two
(28.6%) were diagnosed during workup for new-onset
hypertension caused by catecholamine-secreting lesions.
The final patient with SCP was diagnosed incidentally
on initial screening after an SDHx mutation was identi-
fied in a family member. The mean (SD) size of tumors
in this cohort, all benign lesions, was 4.3 (62.1) cm.
Six patients were treated primarily with angio-
graphic embolization and excision of SCP, leading to uni-
lateral Horner’s syndrome in five of six (83.3%) and
additional CN palsies (X, XII) in four of six (66.7%). The
remaining SCP patient was observed and did not require
definitive treatment during 18 months of follow-up.
Multi-Focal/Metastatic HNPGL
The mean (SD) age of patients with multi-focal or
metastatic HNPGL was 46.5 (613.8) years. Referring to
Figure 1, panel B, SDHD mutations were confirmed in
five patients (patients 2, 4, 6, 17, 18), SDHB mutations
in two (patients 14, 22), SDHC mutations in four
(patients 8, 13, 15, 22), and NF1 mutations in one
(patient 16). Four patients (patients 18, 22–24) in this
cohort were diagnosed with malignant HNPGL due to
the presence of metastatic disease.
DISCUSSION
We present a relatively large cohort of HNPGL
patients, with a strong representation of particularly
rare HNPGL sub-sites (eg, VP, TP, SCP), and evident
diversity in genetic perturbations, diagnostic evaluation,
and treatment protocols. Consistent with previous
reports, there was a strong female predilection of
HNPGL, a broad range of patient age at diagnosis, and
a substantial proportion of patients with a hereditary
predisposition to HNPGL (84.3% among those
tested).20,21 Similarly, the relative prevalence of HNPGL
subsites and SDHx mutations in our cohort (unilateral
CBP and SDHD most common, SCP and SDHA least
common, respectively) closely matches frequency distri-
butions seen in other HNPGL patient cohorts.22
Across all HNPGL subsites at our institution,
screening for functional paragangliomas with plasma or
urine metanephrines was performed in a minority of
HNPGL cases (Figs. 2–4), often in patients who self-
reported a history of hypertension, anxiety, or palpita-
tions or in patients with suspected or confirmed SDHx-
related HNPGL. In total, we identified hypersecreting
HNPGL in nine (4.6%) patients, a proportion skewed
upwards slightly by two patients with paragangliomas
derived from sympathetic, rather than parasympathetic,
paraganglia. Elevation of metanephrines in one patient
presenting with CBP (patient 14, Fig. 1, panel B) led to
a diagnosis of concomitant, hypersecreting para-aortic
paraganglioma. Plasma metanephrines have a marginal
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Fig. 3. Diagnostic evaluation & treatment of patients (n541) with solitary, unilateral jugular paraganglioma (JP). † 2 patients with facial
paralysis or weakness, 3 with neck/occiput pain, 1 with dysarthria, and 1 with altered vision and papilledema. ‡ External carotid artery,
occipital artery, and internal jugular vein
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Fig. 4. Diagnostic evaluation & treatment of patients (n5 21) with solitary, unilateral vagal paraganglioma (VP). † 1 patient with painless
neck swelling/fullness, 1 with pulsatile tinnitus, 1 with dysphagia. ‡ Ascending pharyngeal artery, facial artery, internal carotid artery, external
carotid artery
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Fig. 5. Proposed clinical algorithm for diagnostic evaluation & treatment of HNPGL. Panel A: Beginning with suspected HNPGL, diagnostic
evaluation should commence with patient history and physical exam (1), followed by head and neck imaging (2) to confirm diagnosis of
HNPGL and case presentation at Tumor Board (3). Panel B: Following comprehensive diagnostic evaluation as in panel A, providers should
consider a number of tumor- and patient-related factors when choosing between observation and protocols for active treatment of HNPGL
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sensitivity of roughly 22% for HNPGL, though their util-
ity lies in their near 100% sensitivity for diagnosing a
concomitant catecholamine-secreting paragangliomas at
other sites in SDHx mutation carriers that would
demand prioritized treatment.23,24 Thus, a baseline
assessment of plasma metanephrines should be per-
formed in all patients with HNPGL.
Multimodal imaging techniques were often
employed (Figs. 2–4) in our cohort. Angiography com-
monly supplemented initial contrast-enhanced CT and
MRI in all HNPGL subsites except for TP. Angiography
allowed for mapping of dominant tumor feeding vessels
(eg, ascending pharyngeal artery) in preparation for
embolization and was useful in identifying important
collateral vessels from the internal carotid and vertebral
arteries requiring preservation during surgical extirpa-
tion.8 Baseline and post-treatment audiometry was uni-
formly employed in JP and TP cases to assess long-term
hearing outcomes in these patients.25
In our entire HNPGL cohort, observation with
serial imaging was a popular approach for patients with
small, asymptomatic HNPGL (Figs. 2–4) to define tumor
growth pattern and avoid operative morbidity to lower
cranial nerves. A “watchful waiting” protocol was
employed in 40/194 patients (20.6%) with HNPGL over a
range of 24–73 months of follow-up. A switch to active
treatment planning occurred in seven (17.5%) patients
due to radiologic growth of HNPGL (two CBP, one JP),
pain (one VP), or new cranial nerve dysfunction (two VP,
one SCP). A dearth of retrospective evidence supports
“watchful waiting” as a viable initial management in
appropriately selected HNPGL patients due to indolent
growth patterns and exceedingly low rates of malignant
degeneration or death due to HNPGL progression.26–29
Iatrogenic damage to lower cranial nerves is the
foremost risk in surgical extirpation of HNPGL.30,31
New cranial nerve dysfunction after surgery was seen in
20/49 (40.8%) patients with unilateral CBP and 6/16
(37.5%) patients with JP. The former is a considerably
higher number than in other published reports likely
due to a referral bias favoring a greater number of
Shamblin III tumors treated at our institution.32 Perma-
nent CN X palsy and unilateral Horner’s syndrome was
virtually universal in VP (11/11 patients) and SCP (5/6
patients) cohorts undergoing surgery. Nevertheless, cure
rates afforded by surgery were excellent across all
HNPGL subsites. In the JP cohort, function-preserving,
sub-total resection was followed by adjuvant radiation in
8/14 (51.7%) patients (Fig. 3). In five of these cases,
adjuvant radiation was administered expeditiously after
resection. Conversely, radiation was prompted by tumor
recurrence/regrowth in three cases (roughly one in five
JP patients undergoing sub-total resection) validating
rates of recurrence/regrowth seen in other JP cohorts.33
Increased utilization of this function-preserving
approach to JP treatment may therefore necessitate
patient counseling regarding likelihood of adjuvant
treatment and/or timely adjuvant radiation therapy to
preempt tumor recurrence/regrowth.
At our institution, unilateral and bilateral CBP, JP,
VP, and SCP frequently undergo angiographic
embolization 24–72 hours prior to surgery, though our
data suggest larger size does not reliably influence sur-
geon preference for embolization. At present, there
remains a paucity of strong data on which HNPGL char-
acteristics (eg, size, subsite) predict greater benefit of
preoperative embolization on outcomes.34,35 Therefore, a
best practices approach to HNPGL embolization should
involve a case-based consideration of institutional prefer-
ences, level of interventional/vascular radiology exper-
tise, and tumor-specific factors such as size, subsite, and
proximity to lower CNs.
Fractioned radiation (RT) and stereotactic radiosur-
gery (SRS) produce long-term, durable HNPGL control
and were most commonly employed in our JP and VP
cohorts, providing excellent tumor control over 2–119
months of follow-up and causing no treatment complica-
tions (Figs. (3 and 4)). These therapies are clearly
highly-efficacious, safe alternatives to surgery and are
best suited for patients with large CBP, JP, VP, or multi-
focal HNPGL who have a high likelihood of operative
morbidity to lower cranial nerves or contraindications to
surgery (eg, medical comorbidities).13
Genetic testing for hereditary predisposition to
HNPGL is crucial for active treatment planning, screen-
ing for co-occurring pheochromocytoma and multifocal
tumors, evaluation of at-risk relatives, and in determin-
ing protocols for life-long surveillance.3 Some have pos-
ited a step-by-step strategy for genetic testing based on
clinical features of HNPGL (eg, begin with SDHD or
SDHB testing in multi-focal or malignant HNPGL,
respectively).36 However, although some genotype-
phenotype correlations in specific SDHx-related HNPGL
are evident,37 there is a significant clinical overlap of
syndromes caused by different SDHx mutations. For this
reason, and as genetic testing becomes more accessible
and affordable,38 initial screening for known pathogenic
mutations in all 12 of the known hereditary susceptibil-
ity genes likely improves sensitivity and patient care in
this population.
CONCLUSIONS
Management of each HNPGL case should be indi-
vidualized and tailored to specific patient-, tumor-, and
genetic-factors. However, an algorithmic approach to
management, as we posit (Figure 5) based on our exten-
sive institutional expertise, can provide a general frame-
work for best practices of current HNPGL evaluation
and management.
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